AVDL:NSD-Avadel Pharmaceuticals plc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 4.05

Change

-0.07 (-1.70)%

Market Cap

USD 0.26B

Volume

0.29M

Avg Analyst Target

USD 17.50 (+332.10%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Avadel Pharmaceuticals plc (AVDL) Stock Analysis:
Based on the Avadel Pharmaceuticals plc stock forecasts from 2 analysts, the average analyst target price for Avadel Pharmaceuticals plc is USD 17.50 over the next 12 months. Avadel Pharmaceuticals plc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Avadel Pharmaceuticals plc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Avadel Pharmaceuticals plc’s stock price was USD 4.05. Avadel Pharmaceuticals plc’s stock price has changed by +14.25% over the past week, -38.91% over the past month and -48.41% over the last year.

About

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narco ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-19 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
NBIX Neurocrine Biosciences Inc

+0.42 (+0.49%)

USD8.12B 92.34 60.75
APHA Tilray, Inc

N/A

USD6.86B 60.60 454.68
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
ITCI Intra-Cellular Therapies Inc

-0.77 (-1.32%)

USD5.52B N/A N/A
PCRX Pacira BioSciences Inc

+1.63 (+2.65%)

USD2.79B 66.75 26.46
TLRY Tilray Inc

+0.07 (+1.46%)

USD2.56B 53.54 N/A
CGC Canopy Growth Corporation

+0.28 (+5.01%)

USD2.32B N/A N/A
IRWD Ironwood Pharmaceuticals Inc

+0.05 (+0.44%)

USD1.76B 3.55 7.08
AMPH Amphastar Pharmaceuticals Inc

-0.37 (-1.09%)

USD1.66B 21.02 12.31

ETFs Containing AVDL

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -49.88% 40% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -49.88% 40% F 23% F
Trailing 12 Months  
Capital Gain -50.06% 63% D 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -50.06% 63% D 32% F
Trailing 5 Years  
Capital Gain -58.76% 54% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -58.76% 54% F 16% F
Average Annual (5 Year Horizon)  
Capital Gain 47.82% 88% B+ 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 47.82% 88% B+ 88% B+
Risk Return Profile  
Volatility (Standard Deviation) 161.38% 9% F 8% F
Risk Adjusted Return 29.63% 81% B- 57% F
Market Capitalization 0.26B 63% D 44% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 60.92 21% F 16% F
Price/Book Ratio 4.06 27% F 21% F
Price / Cash Flow Ratio -3.31 70% C- 66% D
EV/EBITDA 158.68 9% F 5% F
Management Effectiveness  
Return on Equity -64.30% 51% F 18% F
Return on Invested Capital -27.29% 55% F 29% F
Return on Assets -19.14% 43% F 21% F
Debt to Equity Ratio 181.99% 22% F 12% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 4.49 53% F 37% F
Short Percent 7.75% 37% F 23% F
Beta 0.99 54% F 57% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.